Why is $PTGX moving today? · SEC 8-K archive

$PTGX SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $PTGX: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $PTGX filing catalyst

Why did $PTGX trigger an AI stock catalyst alert?

$PTGX triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +7.5/10). Headline: Protagonist Reports Q3 Net Income of $220M on $275M Milestone Payment Following FDA Approval. Key points: - Revenue surged to $274.5M driven by a $275M milestone payment triggered by FDA approval of MIMRYLO. - Diluted EPS reached $3.07 (GAAP net income $220.0M) compared to a diluted loss of $(0.62) in Q3 2025. - Company previously announced a $300M share repurchase program in September 2026.

How did $PTGX stock react after the SEC filing?

After the SEC 8-K for $PTGX, observed market reaction: T0 price $135.26. Past moves do not guarantee future results.

Where can I get real-time $PTGX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $PTGX via Telegram and the VIP Web Terminal from €10/month.

$PTGX – Protagonist Reports Q3 Net Income of $220M on $275M Milestone Payment Following FDA Approval

Protagonist Therapeutics, Inc
· SEC 8-K · All $PTGX

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+7.5 / 10)
  • Revenue surged to $274.5M driven by a $275M milestone payment triggered by FDA approval of MIMRYLO.
  • Diluted EPS reached $3.07 (GAAP net income $220.0M) compared to a diluted loss of $(0.62) in Q3 2025.
  • Company previously announced a $300M share repurchase program in September 2026.